Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu, Roberto A. Ortega, Marta San Luciano, Anat Mirelman, Claustre Pont-Sunyer, Kathrin Brockmann, Dolores Vilas, Eduardo Tolosa, Daniela Berg, Bjørg Warø, Amanda Glickman, Deborah Raymond, Rivka Inzelberg, Javier Ruiz-Martinez, Elisabet Mondragon, Eitan Friedman, Sharon Hassin-Baer, Roy N. Alcalay, Helen Mejia-Santana, Jan AaslyTatiana Foroud, Karen Marder, Nir Giladi, Susan Bressman, Rachel Saunders-Pullman

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

Original languageEnglish (US)
Pages (from-to)1392-1398
Number of pages7
JournalMovement disorders : official journal of the Movement Disorder Society
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Leucine
Parkinson Disease
Phosphotransferases
Mutation
Neoplasms
Odds Ratio
Confidence Intervals
Leukemia
Skin Neoplasms
Colonic Neoplasms
Logistic Models

Keywords

  • colon cancer
  • G2019S mutation
  • leukemia
  • LRRK2 gene
  • Parkinson's disease
  • pooled analysis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. / Agalliu, Ilir; Ortega, Roberto A.; Luciano, Marta San; Mirelman, Anat; Pont-Sunyer, Claustre; Brockmann, Kathrin; Vilas, Dolores; Tolosa, Eduardo; Berg, Daniela; Warø, Bjørg; Glickman, Amanda; Raymond, Deborah; Inzelberg, Rivka; Ruiz-Martinez, Javier; Mondragon, Elisabet; Friedman, Eitan; Hassin-Baer, Sharon; Alcalay, Roy N.; Mejia-Santana, Helen; Aasly, Jan; Foroud, Tatiana; Marder, Karen; Giladi, Nir; Bressman, Susan; Saunders-Pullman, Rachel.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 34, No. 9, 01.09.2019, p. 1392-1398.

Research output: Contribution to journalArticle

Agalliu, I, Ortega, RA, Luciano, MS, Mirelman, A, Pont-Sunyer, C, Brockmann, K, Vilas, D, Tolosa, E, Berg, D, Warø, B, Glickman, A, Raymond, D, Inzelberg, R, Ruiz-Martinez, J, Mondragon, E, Friedman, E, Hassin-Baer, S, Alcalay, RN, Mejia-Santana, H, Aasly, J, Foroud, T, Marder, K, Giladi, N, Bressman, S & Saunders-Pullman, R 2019, 'Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls', Movement disorders : official journal of the Movement Disorder Society, vol. 34, no. 9, pp. 1392-1398. https://doi.org/10.1002/mds.27807
Agalliu, Ilir ; Ortega, Roberto A. ; Luciano, Marta San ; Mirelman, Anat ; Pont-Sunyer, Claustre ; Brockmann, Kathrin ; Vilas, Dolores ; Tolosa, Eduardo ; Berg, Daniela ; Warø, Bjørg ; Glickman, Amanda ; Raymond, Deborah ; Inzelberg, Rivka ; Ruiz-Martinez, Javier ; Mondragon, Elisabet ; Friedman, Eitan ; Hassin-Baer, Sharon ; Alcalay, Roy N. ; Mejia-Santana, Helen ; Aasly, Jan ; Foroud, Tatiana ; Marder, Karen ; Giladi, Nir ; Bressman, Susan ; Saunders-Pullman, Rachel. / Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. In: Movement disorders : official journal of the Movement Disorder Society. 2019 ; Vol. 34, No. 9. pp. 1392-1398.
@article{13101ad46512450eb9ec587b74e8f327,
title = "Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls",
abstract = "BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3{\%}), IPD patients (27.5{\%}), and controls (27.5{\%}; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95{\%} confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95{\%} CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95{\%} CI, 2.15-44.94) and colon cancer (OR = 2.34; 95{\%} CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.",
keywords = "colon cancer, G2019S mutation, leukemia, LRRK2 gene, Parkinson's disease, pooled analysis",
author = "Ilir Agalliu and Ortega, {Roberto A.} and Luciano, {Marta San} and Anat Mirelman and Claustre Pont-Sunyer and Kathrin Brockmann and Dolores Vilas and Eduardo Tolosa and Daniela Berg and Bj{\o}rg War{\o} and Amanda Glickman and Deborah Raymond and Rivka Inzelberg and Javier Ruiz-Martinez and Elisabet Mondragon and Eitan Friedman and Sharon Hassin-Baer and Alcalay, {Roy N.} and Helen Mejia-Santana and Jan Aasly and Tatiana Foroud and Karen Marder and Nir Giladi and Susan Bressman and Rachel Saunders-Pullman",
year = "2019",
month = "9",
day = "1",
doi = "10.1002/mds.27807",
language = "English (US)",
volume = "34",
pages = "1392--1398",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

AU - Agalliu, Ilir

AU - Ortega, Roberto A.

AU - Luciano, Marta San

AU - Mirelman, Anat

AU - Pont-Sunyer, Claustre

AU - Brockmann, Kathrin

AU - Vilas, Dolores

AU - Tolosa, Eduardo

AU - Berg, Daniela

AU - Warø, Bjørg

AU - Glickman, Amanda

AU - Raymond, Deborah

AU - Inzelberg, Rivka

AU - Ruiz-Martinez, Javier

AU - Mondragon, Elisabet

AU - Friedman, Eitan

AU - Hassin-Baer, Sharon

AU - Alcalay, Roy N.

AU - Mejia-Santana, Helen

AU - Aasly, Jan

AU - Foroud, Tatiana

AU - Marder, Karen

AU - Giladi, Nir

AU - Bressman, Susan

AU - Saunders-Pullman, Rachel

PY - 2019/9/1

Y1 - 2019/9/1

N2 - BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

AB - BACKGROUND: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. METHODS: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. RESULTS: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46-10.61) and skin cancer (OR = 1.61; 95% CI, 1.09-2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15-44.94) and colon cancer (OR = 2.34; 95% CI, 1.15-4.74) when compared with IPD patients. CONCLUSIONS: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

KW - colon cancer

KW - G2019S mutation

KW - leukemia

KW - LRRK2 gene

KW - Parkinson's disease

KW - pooled analysis

UR - http://www.scopus.com/inward/record.url?scp=85072546686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072546686&partnerID=8YFLogxK

U2 - 10.1002/mds.27807

DO - 10.1002/mds.27807

M3 - Article

C2 - 31348549

AN - SCOPUS:85072546686

VL - 34

SP - 1392

EP - 1398

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 9

ER -